



Argutus Medical (Formerly Biotin International) is an Irish company specialising in the discovery, development and promotion of cell specific BMs of early kidney, liver and pancreas injury. Argutus has been providing novel BMs to the pharmaceutical industry, research and medical communities since 1994. Argutus's excellence in the development of novel BMs is indicated by their contribution to the International Life Sciences Consortium on novel renal preclinical BMs. Argutus developed three novel biomarker assays which were submitted to the FDA and EMEA for acceptance as qualified BMs in 2008.

Argutus has great expertise in the discovery and development of novel BMs for studying renal and hepatic injury. Argutus's Histomics® technology enables specific BMs to be identified from biological samples by immunohistological screening. Argutus's BMs are validated against histological changes in the organ being studied, the gold standard of pathological diagnosis. Over one hundred publications have been created based on Biotin's BMs, providing a solid base on which to build new studies.

www.argutusmed.com